miR-342-5p inhibits osteosarcoma cell growth, migration, invasion, and sensitivity to Doxorubicin through targeting Wnt7b

References

• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
   PubMedGoogle Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.
   PubMed Web of Science ®Google Scholar
• Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011;2011:959248.
   PubMedGoogle Scholar
• He JP, Hao Y, Wang XL, et al. Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev. 2014;15:5967–5976.
   PubMedGoogle Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.
   PubMedGoogle Scholar
• Zhang J, Yu XH, Yan YG, et al. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta. 2015;444:182–192.
   PubMed Web of Science ®Google Scholar
• Hu K, Dai HB, Qiu ZL. mTOR signaling in osteosarcoma: oncogenesis and therapeutic aspects (Review). Oncol Rep. 2016;36:1219–1225.
   PubMed Web of Science ®Google Scholar
• Zhang A, He S, Sun X, et al. Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals. Cancer Cell Int. 2014;14:15.
   PubMed Web of Science ®Google Scholar
• Chen J, Tu X, Esen E, et al. WNT7B promotes bone formation in part through mTORC1. PLoS Genet. 2014;10:e1004145.
   PubMed Web of Science ®Google Scholar
• Bui TD, O’Brien T, Crew J, et al. High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer. Br J Cancer. 1998;77:319–324.
   PubMed Web of Science ®Google Scholar
• Kirikoshi H, Sekihara H, Katoh M. Molecular cloning and characterization of human WNT7B. Int J Oncol. 2001;19:779–783.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.
   PubMed Web of Science ®Google Scholar
• He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett. 2014;7:1352–1362.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Ding M, Ni J, et al. MiR-142 acts as a tumor suppressor in osteosarcoma cell lines by targeting Rac1. Oncol Rep. 2015;33:1291–1299.
   PubMed Web of Science ®Google Scholar
• Li H, Zhang K, Liu LH, et al. MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma. Oncol Lett. 2015;10:1662–1668.
   PubMed Web of Science ®Google Scholar
• Diao CY, Guo HB, Ouyang YR, et al. Screening for metastatic osteosarcoma biomarkers with a DNA microarray. Asian Pac J Cancer Prev. 2014;15:1817–1822.
   PubMedGoogle Scholar
• Wang Z, He R, Xia H, et al. MicroRNA-101 has a suppressive role in osteosarcoma cells through the targeting of c-FOS. Exp Ther Med. 2016;11:1293–1299.
   PubMed Web of Science ®Google Scholar
• Ji F, Zhang H, Wang Y, et al. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone. 2013;56:220–226.
   PubMed Web of Science ®Google Scholar
• Jin J, Cai L, Liu ZM, et al. miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 2013;14:3681–3684.
   PubMedGoogle Scholar
• Wang J, Xu G, Shen F, et al. miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells. Tumour Biol. 2014;35:4859–4865.
   PubMedGoogle Scholar
• Xu H, Mei Q, Shi L, et al. Tumor-suppressing effects of miR451 in human osteosarcoma. Cell Biochem Biophys. 2014;69:163–168.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yang X, Fu C, et al. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/beta-catenin signaling pathway. Gene. 2018;672:172–179.
   PubMed Web of Science ®Google Scholar
• Shiah SG, Hsiao JR, Chang WM, et al. Downregulated miR329 and miR410 promote the proliferation and invasion of oral squamous cell carcinoma by targeting Wnt-7b. Cancer Res. 2014;74:7560–7572.
   PubMed Web of Science ®Google Scholar
• Grady WM, Parkin RK, Mitchell PS, et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene. 2008;27:3880–3888.
   PubMed Web of Science ®Google Scholar
• Cittelly DM, Das PM, Spoelstra NS, et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010;9:317.
   PubMed Web of Science ®Google Scholar
• Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111:E5564–73.
   PubMed Web of Science ®Google Scholar
• Zhou W, Hao M, Du X, et al. Advances in targeted therapy for osteosarcoma. Discov Med. 2014;17:301–307.
   PubMed Web of Science ®Google Scholar
• Liu ZB, Wang JA, Lv RQ. Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis. Eur Rev Med Pharmacol Sci. 2019;23:1418–1427.
   PubMed Web of Science ®Google Scholar
• Arensman MD, Kovochich AN, Kulikauskas RM, et al. WNT7B mediates autocrine Wnt/beta-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma. Oncogene. 2014;33:899–908.
   PubMed Web of Science ®Google Scholar
• Zheng D, Decker KF, Zhou T, et al. Role of WNT7B-induced noncanonical pathway in advanced prostate cancer. Mol Cancer Res. 2013;11:482–493.
   PubMed Web of Science ®Google Scholar
• Yang H, Li Q, Niu J, et al. microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10. Oncotarget. 2016;7:2709–2720.
   PubMedGoogle Scholar
• Lindholm EM, Leivonen SK, Undlien E, et al. miR-342-5p as a potential regulator of HER2 breast cancer cell growth. Microrna. 2019;8:155–165.
   PubMedGoogle Scholar
• Lin CH, Ji T, Chen CF, et al. Wnt signaling in osteosarcoma. Adv Exp Med Biol. 2014;804:33–45.
   PubMed Web of Science ®Google Scholar
• Ma Y, Ren Y, Han EQ, et al. Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun. 2013;431:274–279.
   PubMed Web of Science ®Google Scholar
• Papagiannakopoulos T, Kosik KS. MicroRNAs: regulators of oncogenesis and stemness. BMC Med. 2008;6:15.
   PubMed Web of Science ®Google Scholar
• Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423–436.
   PubMed Web of Science ®Google Scholar
• Fujii H, Honoki K, Tsujiuchi T, et al. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol. 2009;34:1381–1386.
   PubMed Web of Science ®Google Scholar
• Gillette J, Nielsen-Preiss S. Cancer stem cells: seeds of growth in osteosarcoma. Cancer Biol Ther. 2009;8:553–554.
   PubMed Web of Science ®Google Scholar
• Yu F, Deng H, Yao H, et al. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29:4194–4204.
   PubMed Web of Science ®Google Scholar
• Radisky DC. miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype. Breast Cancer Res. 2011;13:110.
   PubMed Web of Science ®Google Scholar
• Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211–215.
   PubMed Web of Science ®Google Scholar